- Advising stakeholders on Medicare coverage and reimbursement matters before the Centers for Medicare & Medicaid Services (CMS).
- Counseling Medicare Advantage organizations and related entities on regulatory compliance and policy issues.
- Representing Medicare Advantage Special Needs Plans (SNPs) before federal regulators and Congress on legislative, regulatory, and policy matters.
- Advocating on Medicare reimbursement, physician payment, and related health care financing issues.
- Providing legislative and policy counsel to leading physician organizations.
- Advising stakeholders on legislative and regulatory compliance issues related to pharmacy benefit manager (PBM) policies across commercial, Medicare, and Medicaid markets.
- Drafting comment letters and regulatory submissions on behalf of industry stakeholders in response to proposed regulations, requests for information, and legislative proposals.
- Counseling health care stakeholders on federal and state price transparency requirements and policy developments.
- Analyzing annual notice of benefit and payment parameters (NBPP) rulemaking and advise health plan clients on regulatory implications.
- Advising clients on emerging legislative, regulatory, and litigation developments related to the No Surprises Act.
- Providing strategic counsel and regulatory analysis regarding Medicare Advantage star ratings, including matters associated with ongoing litigation.
- Advising Medicare Advantage organizations on regulatory interpretation and compliance considerations to support business and operational decisions.
- Counseling health insurance stakeholders on legislative, regulatory, and litigation developments affecting Affordable Care Act eligibility, enrollment, and verification requirements.
- Advising Medicare Advantage organizations on state and federal requirements governing agent and broker compensation.
- Analyzing and advising on regulatory developments involving CMS and Drug Enforcement Administration (DEA) telehealth policies.
Sofia V. Molodanof
- Phone: +1 202 239 3170
- Email: sofia.molodanof@alston.com
Sofia Molodanof provides regulatory, legislative, and policy counsel to health plans, physician organizations, and other health care stakeholders navigating an increasingly complex landscape. She focuses her practice on Medicare Advantage, Affordable Care Act market reforms, Medicare payment policy, price transparency requirements, and emerging policy developments. She advises clients on regulatory and litigation developments, drafts advocacy materials for federal agencies and Congress, and helps organizations prepare for changes in health care policy.
Sofia previously interned for the Senate Committee on Health, Education, Labor, and Pensions (HELP), the House Committee on Oversight and Reform, Select Subcommittee on the Coronavirus Crisis, and for Representative Doris Matsui (CA-07). While on Capitol Hill, she had the opportunity to focus on health care issues and legislation related to public health, Medicare, Medicaid, and the ACA.
Sofia was a law clerk at the U.S. Department of Health and Human Services, Office of Counsel to the Inspector General, working on regulatory and compliance issues regarding fraud, waste, and abuse in federal programs and arising from various HHS operating divisions. Sofia also interned with the Department of Justice, Office of Vaccine Litigation, where she assisted in all stages of litigation involving vaccine-related tort claims, and with the Hon. Rosemary M. Collyer of the U.S. District Court for the District of Columbia.
Sofia was recognized in Best Lawyers: Ones to Watch® for Health Care Law.
Bar Admissions
- California
- District of Columbia
Education
- Georgetown University (J.D., 2021)
- University of California, Davis (B.A., 2018)
Memberships
- American Health Law Association
Healthy Byte | DEA and HHS Finalize Rule on Prescribing Buprenorphine via Telemedicine – Or Did They?
Sean Sullivan, Sofia Molodanof, and Anthony Fanucci examine the final rule on prescribing buprenorphine via telemedicine that was published on January 15, 2025. They discuss the key components of the rule, the implication it leaves for stakeholders, and whether the Trump Administration could revise or kill the rule.